Deferred Tax Assets, Gross of Can-Fite BioPharma Ltd. from 31 Dec 2018 to 31 Dec 2024

Taxonomy & unit: us-gaap: USD
Description: Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.
Summary: Can-Fite BioPharma Ltd. quarterly Deferred Tax Assets, Gross in USD history and change rate from 31 Dec 2018 to 31 Dec 2024.
Can-Fite BioPharma Ltd. Deferred Tax Assets, Gross for the quarter ending 31 Dec 2024 was $28,060,000, a 5.2% increase year-over-year.
Source SEC data: View on sec.gov

Deferred Tax Assets, Gross, Quarterly (USD)

Deferred Tax Assets, Gross, YoY Quarterly Change (%)

Can-Fite BioPharma Ltd. Quarterly Deferred Tax Assets, Gross (USD)

Period	Value	YoY Chg	Change %	Date	Report	Filed	Fiscal Year	Fiscal Period
Q4 2024	$28,060,000	+$1,398,000	+5.2%	31 Dec 2024	20-F	14 Apr 2025	2024	FY
Q4 2023	$26,662,000	+$149,000	+0.56%	31 Dec 2023	20-F	14 Apr 2025	2024	FY
Q4 2022	$26,513,000	-$2,120,000	-7.4%	31 Dec 2022	20-F	28 Mar 2024	2023	FY
Q4 2021	$28,633,000	-$7,260,000	-20%	31 Dec 2021	20-F	30 Mar 2023	2022	FY
Q4 2020	$35,893,000	+$6,364,000	+22%	31 Dec 2020	20-F	24 Mar 2022	2021	FY
Q4 2019	$29,529,000	+$5,199,000	+21%	31 Dec 2019	20-F	25 Mar 2021	2020	FY
Q4 2018	$24,330,000			31 Dec 2018	6-K	01 Jun 2020	2019	FY

* An asterisk sign (*) next to the value indicates that the value is likely invalid.